JORC resource expected “imminently” for MTA

Published 13-NOV-2015 08:35 A.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Metals of Africa (ASX:MTA) is expecting a JORC resource for key deposits at its Montepuez Central graphite project “imminently” after receiving the last of high grade results back from the lab.

MTA has drilled 60 diamond holes at Montepuez over the past year, targeting the Elephant, Buffalo, and Lion prospects.

Today it told shareholders that it had received the last of the assays from this drilling, with the latest results covering the Buffalo prospect.

It said that results included 100.7m @ 11.5% total graphitic content and 0.26% vanadium from 2m, and 94.8m @ 8.79% TGC and 0.25% vanadium from 1m.

With all the lab assays back, the numbers are now with an independent resource estimation geologist, who is currently doing the sums on a JORC resource.

Managing director Cherie Leeden said the latest assay results confirmed her thinking about the project.

“These exceptional results are in line with our previously reported intersections and give us continued confidence that our maiden resource will confirm that we are extremely undervalued compared to our peers,” she said.

About Montepuez Central

Its flagship graphite project is at the Montepuez Central Graphite Project in the prolific Cabo Delgado graphite province.

So far, it has found three key prospects at the Montepuez Central Graphite Project including the Buffalo, Elephant, and Lion prospects.

The location of MTA's projects in Mozambique

The location of MTA’s projects in Mozambique

Meanwhile to the south it is currently drilling at the Balama Central project.

The project is along strike (on electromagnetic data) to projects being done by both Syrah Resources (ASX:SYR) and Triton Minerals (ASX:TON), and MTA recently confirmed chip samples taken at Balama Central were high-grade in nature.

Rock chip samples brought up grades of up to 17.55% total graphitic carbon (TGC) and 0.364% Vanadium.

The ASX-listed company has been conducting an ongoing pitting program at the Balama Central Project to test an anomaly brought up by a previous VTEM survey.

tags

GRAPHITE


General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X